Company profile
Krystal Biotech, Inc.
NASDAQ: KRYS · Healthcare · Biotechnology
#230 of 1,418 Healthcare companies by revenue73rd-percentile growth
EA Score
77B+FH 93DQ 53GM —SS 72
v0.1 · 55/100 weight · provisional
↑ net margin, operating margin · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$440.5M
Rev growth YoY (TTM)
+22.6%
Net income (FY)
$204.8M
Employees
295
as of 2026-08-06
Market cap
$9.6B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$389.1M$389.1M2025
Net income$204.8M$204.8M2025
Operating income$161.3M$161.3M2025
Total assets$1.3B$1.3B2025
Liabilities$114.2M$114.2M2025
Equity$1.2B$1.2B2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Krystal Biotech, Inc.’s revenue?
Krystal Biotech, Inc. booked $389.1M in FY2025 revenue, growing 34% year over year — faster than most Healthcare companies we track, at a 52.6% net margin.
Peers · Healthcare
Innoviva, Inc.83B+Ardelyx, Inc.68BEsperion Therapeutics, Inc.61CSonida Senior Living, Inc.64CCareDx, Inc78B+Twist Bioscience Corporation70BNeighbors
Allegheny →Key facts
CEOKrish S. Krishnan
SectorHealthcare
IndustryBiotechnology
HeadquartersPittsburgh, PA
ExchangeNASDAQ: KRYS
Employees295
IPO date2017-09-20
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.